Basit öğe kaydını göster

The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

dc.contributor.authorArslan, Cagatay
dc.contributor.authorYekeduz, Emre
dc.contributor.authorTural, Deniz
dc.contributor.authorErturk, Ismail
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorEROL, CİHAN
dc.contributor.authorErcelep, Ozlem
dc.contributor.authorSever, Ozlem Nuray
dc.contributor.authorÜRÜN, YÜKSEL
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorŞENDUR, MEHMET ALİ NAHİT
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorCan, Orcun
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorSenturk Oztas, Nihan
dc.contributor.authorKILIÇKAP, SAADETTİN
dc.date.accessioned2022-07-04T15:22:39Z
dc.date.available2022-07-04T15:22:39Z
dc.identifier.citationYekeduz E., Tural D., Erturk I., Karakaya S., EROL C., Ercelep O., Arslan C., Sever O. N. , KILIÇKAP S., Senturk Oztas N., et al., "The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022
dc.identifier.issn0171-5216
dc.identifier.othervv_1032021
dc.identifier.otherav_aba155b8-6686-4b3a-81fb-c3b41fa0ab10
dc.identifier.urihttp://hdl.handle.net/20.500.12627/184183
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/aba155b8-6686-4b3a-81fb-c3b41fa0ab10/file
dc.identifier.urihttps://doi.org/10.1007/s00432-022-04055-5
dc.description.abstractBackground Pan-immune-inflammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.
dc.language.isoeng
dc.subjectOncology
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectHealth Sciences
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.titleThe relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study
dc.typeMakale
dc.relation.journalJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
dc.contributor.departmentAnkara Üniversitesi , ,
dc.contributor.firstauthorID3425426


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster